KENNETH LOWRY: Open Payments
NPI 1932773306 · SALEM, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$694 in 33 payments from 11 companies in 2025. Trend: 2023 $941 · 2024 $575 · 2025 $694
Food & beverage: $694
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 8 | $179 |
| E.R. Squibb & Sons, L.L.C. | 4 | $88 |
| Novo Nordisk Inc | 4 | $70 |
| Amgen Inc. | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $65 |
| Merck Sharp & Dohme LLC | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| CORDIS US CORP. | 1 | $19 |
Products named: ELIQUIS, VYNDAQEL, Wegovy, REPATHA, JARDIANCE, VERQUVO, LEQVIO, AMVUTTRA.
Industry payments across OR — which companies pay providers there.
